The half hemolysis rate test is a fundamental biocompatibility assay used to quantify the hemolytic potential of blood-contacting medical devices, biomaterials, and parenteral products. A well-designed test protocol, aligned with ISO 10993-4, ASTM F756, and GB/T 16886.4, delivers reproducible data on red blood cell lysis and directly supports regulatory submissions worldwide. This article explains the principles, sample requirements, test items, methodologies, and protocol design considerations behind the 50% hemolysis assay.
Technical Overview
Hemolysis is the rupture of red blood cells (erythrocytes) and the subsequent release of hemoglobin into the surrounding plasma or test medium. For any medical device that contacts circulating blood, either directly or indirectly, hemolysis is one of the most sensitive early indicators of physical trauma or chemical toxicity. A high hemolysis rate can signal sharp edges, abrasive surfaces, residual processing agents, or leachable substances capable of damaging erythrocyte membranes.
The half hemolysis rate test quantifies the percentage of red blood cells lysed after controlled exposure to a test sample. Released hemoglobin is measured spectrophotometrically in the range of 540–545 nm, and the result is normalized against negative and positive controls using the standard formula: Hemolysis Rate (%) = (A_test − A_negative) / (A_positive − A_negative) × 100. The "half" or 50% hemolysis concept originates from complement-mediated lysis assays, where 50% hemolysis (CH50) represents the reference endpoint of the sigmoidal dose–response curve and defines the linear region in which measurement is most precise. The same statistical logic underpins the design of modern material hemolysis protocols, ensuring readings fall within the reliable detection window.
Protocol design is governed by an internationally harmonized framework of standards, including ISO 10993-4 (selection of tests for interactions with blood), ISO 10993-12 (sample preparation and reference materials), ASTM F756 (assessment of hemolytic properties of materials), and the Chinese national equivalent GB/T 16886.4. Under ASTM F756, materials are classified by hemolytic index: non-hemolytic (≤ 2%), slightly hemolytic (> 2% to ≤ 5%), and hemolytic (> 5%). Most regulatory authorities expect a hemolysis rate below 5% for blood-contacting devices intended for human use.
Testing Samples
Blood-Contacting Medical Devices
Finished devices in their final, sterilized, and clinically representative condition constitute the primary test population. Typical examples include:
- Intravascular catheters, cannulae, guidewires, and introducer sheaths
- Vascular stents, stent grafts, and artificial blood vessels
- Heart valves, oxygenators, hemodialyzers, and extracorporeal circulation tubing sets
- Blood bags, syringes, infusion sets, and needles
- Ventricular assist devices and ECMO circuit components
Raw Biomaterials and Surface Modifications
During research and development, candidate polymers, metals, ceramics, hydrogel coatings, and antithrombotic surface treatments are screened before device-level testing. Coupons with defined surface area and thickness are prepared to mimic the final manufacturing and sterilization processes.
Pharmaceutical and Biological Products
Injectable formulations, contrast agents, biologics, lipid-based carriers, and nanomaterials intended for intravenous administration are evaluated for their capacity to lyse erythrocytes in vitro prior to in vivo safety studies.
Control Materials
Every protocol incorporates a negative control with negligible hemolytic activity (for example, high-density polyethylene reference material or physiological saline) and a positive control inducing complete hemolysis (such as sterile water for injection, sodium dodecyl sulfate, or a nonionic surfactant solution). Control validity criteria are established before the study begins.
Testing Items
Depending on device classification, blood contact duration, and the biological evaluation plan, the protocol may include the following test items:
- Hemolysis rate (hemolytic index) determination by direct contact method
- Hemolysis rate determination by indirect extraction method
- Plasma free hemoglobin quantification in dynamic circulation models
- Hemolytic classification in accordance with ASTM F756 criteria
- Total hemolytic complement activity (CH50, 50% hemolysis endpoint) using sensitized sheep erythrocytes
- Complement activation markers such as C3a, C5a, and SC5b-9 per ISO 10993-4
- Supplementary hematology parameters including erythrocyte count and morphology assessment
Testing Methods
Direct Contact Method
The test sample is placed in direct contact with fresh, diluted, anticoagulated blood, typically from healthy rabbits or human donors. The mixture is incubated at 37 ± 1 °C for a defined period, commonly three to four hours, with periodic gentle inversion to ensure uniform exposure. After incubation, samples are centrifuged to remove intact cells, and the supernatant absorbance is measured at 540–545 nm. This method best suits devices whose hemolytic risk arises from surface geometry, shear interaction, or direct material contact.
Indirect Contact (Extraction) Method
An extract of the test article is first prepared in accordance with ISO 10993-12, using physiological saline or other appropriate vehicles at a defined surface-area-to-volume ratio, commonly 3 cm²/mL for regular surfaces or 0.1–0.2 g/mL for irregular or porous materials. Standard extraction conditions include 37 °C for 24 hours to simulate clinical use, with exaggerated conditions such as 50 °C for 72 hours or 70 °C for 24 hours applied when a worst-case assessment is required. The extract is then incubated with diluted blood, and hemoglobin release is quantified as above. This method captures hemolysis caused by leachable chemical substances.
Spectrophotometric Quantification and Calculation
Following incubation and centrifugation, the absorbance of each supernatant is measured against a blank. The hemolysis rate is calculated as (A_test − A_negative) / (A_positive − A_negative) × 100%. Samples with intrinsic color or turbidity require parallel blanks to correct for optical interference. Results are reported as the mean of at least three replicates with standard deviation, and the hemolytic classification is assigned against ASTM F756 thresholds.
50% Hemolysis (CH50) Endpoint Determination
For complement activity assessment, antibody-sensitized sheep erythrocytes are incubated with serial dilutions of serum in veronal-buffered saline containing calcium and magnesium ions. After incubation at 37 °C and centrifugation, hemoglobin release is measured at approximately 541 nm. The percentage of lysis at each dilution is transformed using the von Krogh equation, and the dilution producing exactly 50% hemolysis defines the CH50 value, reported in units per milliliter. This endpoint is chosen because the dose–response curve is steepest and most linear at the midpoint, maximizing analytical sensitivity.
Protocol Design Considerations
- Blood source, donor number, and anticoagulant selection (heparin, ACD, or citrate; EDTA is avoided when complement endpoints are included)
- Extraction ratio, vehicle, and condition selection justified against intended clinical use
- Incubation time, temperature, and agitation regime matched to device geometry and blood contact duration
- Replicate number, acceptance criteria for controls, and statistical analysis plan defined in the protocol before testing
- Interference assessment for colored, turbid, or protein-rich samples
- Sample preparation reflecting the final sterilization state and packaging configuration
Applications
Half hemolysis rate test data serve multiple functions across the product lifecycle of blood-contacting devices:
- Regulatory submission support for device registration under NMPA, FDA, EU MDR, and other national frameworks, forming part of the ISO 10993-1 biological evaluation file
- Design verification for new catheters, stents, oxygenators, dialyzers, and infusion devices prior to clinical investigation
- Material screening and comparative evaluation of surface coatings, antithrombotic treatments, and polymer formulations
- Change control assessment following modification of materials, suppliers, manufacturing processes, or sterilization methods
- Supporting evidence within extractables and leachables studies and toxicological risk assessments
- Preclinical safety screening of intravenous pharmaceutical formulations and drug-device combination products
Manufacturers frequently engage accredited third-party laboratories to execute these protocols under GLP or ISO/IEC 17025 quality systems, ensuring that data are generated with documented traceability and are acceptable to global regulatory reviewers.
FAQ
What hemolysis rate is considered acceptable for a medical device?
A hemolysis rate of 5% or less is generally regarded as the acceptance threshold for blood-contacting devices in most regulatory jurisdictions. Under the ASTM F756 classification scheme, results at or below 2% are considered non-hemolytic, results above 2% up to 5% are slightly hemolytic, and results above 5% are hemolytic and typically require material or design remediation.
How do I choose between the direct contact method and the extraction method?
The direct contact method is appropriate when the hemolytic hazard relates to the physical surface of the device, such as edges, texture, or flow-induced shear. The extraction method is preferred when the concern is chemical leachables from materials, adhesives, plasticizers, or sterilization residues. Many protocols combine both methods to provide comprehensive coverage of mechanical and chemical hemolytic mechanisms.
What blood source and anticoagulant are used in the assay?
Fresh rabbit blood and human donor blood are both widely accepted. Heparin, acid-citrate-dextrose (ACD), and sodium citrate are the most common anticoagulants because they preserve erythrocyte integrity and complement activity. EDTA is avoided when complement-related endpoints such as CH50 are included, since it chelates divalent ions essential for the complement cascade.
How does the CH50 50% hemolysis endpoint differ from the material hemolysis rate?
The CH50 assay measures the functional activity of the complement system in serum by identifying the dilution that lyses 50% of a standardized suspension of sensitized erythrocytes. The material hemolysis rate, by contrast, measures the percentage of red blood cells lysed by a test article or its extract. The former evaluates a biological effector system, while the latter evaluates the hemolytic property of the device itself.
How are colored or turbid samples handled?
Samples containing pigments, particles, or proteins can bias absorbance readings at 540–545 nm. The protocol must include sample-specific blanks, alternative hemoglobin detection wavelengths, or validated correction procedures to ensure that reported hemolysis rates reflect true hemoglobin release rather than optical interference.
How many replicates and donors are required?
Most protocols require a minimum of three replicate determinations per group, and ISO 10993-4 recommends blood from multiple donors where feasible to account for biological variability. Control acceptance ranges, such as positive control readings approaching complete lysis and negative control readings near baseline, must be predefined in the study protocol.